Nautilus Biotechnology annual operating income
2020
2022
2023
2024
2025
Nautilus Biotechnology Operating Income Growth & History (NAUT)
Nautilus Biotechnology's operating income was −$66.8M for fiscal 2025.
View full Nautilus Biotechnology company overviewNautilus Biotechnology annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$66.8M | $14.6M | — |
| 2024 | 2024-12-31 | −$81.5M | −$5.3M | — |
| 2023 | 2023-12-31 | −$76.2M | −$12.5M | — |
| 2022 | 2022-12-31 | −$63.6M | — | — |
| 2020 | 2020-12-31 | −$576,035 | — | — |
Nautilus Biotechnology quarterly operating income
Q3.20
Q1.21
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.8M | $1.3M | — |
| Q1 2026 | 2026-03-31 | −$16.1M | — | — |
| Q4 2025 | 2025-12-31 | −$15.4M | — | — |
| Q3 2025 | 2025-09-30 | −$15.5M | — | — |
| Q2 2025 | 2025-06-30 | −$17.1M | — | — |
| Q1 2021 | 2021-03-31 | −$1.8M | — | — |
| Q3 2020 | 2020-09-30 | −$174,671 | — | — |
Nautilus Biotechnology operating income trends
Over the last five fiscal years, Nautilus Biotechnology's operating income decreased from −$576,035 to −$66.8M, a change of −$66.3M. The latest reported quarter, Q2 2026, shows −$15.8M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nautilus Biotechnology source filings ↗